Knockout Cell Lines

Home > Gene Editing Services > Stable Cell Lines > Knockout Cell Lines

Gene Knockout Cell Line

Knockout cell lines serve as crucial research models, widely used in exploring gene functions, disease mechanisms, and drug target screening. By simulating the effects of gene deletion on cellular behavior, it can reveal the roles of specific genes in biological processes and their significance in disease development.

Based on the CRISPR-U™ technique, Ubigene selects appropriate transfection methods (electroporation or viral transduction) according to different cell characteristics to transfer gRNA and Cas9 into cells. Subsequently, single-cell clone screening is performed, and positive clones that are successfully knocked out will be validated by target site amplification and sequencing. Final deliverables will be the homozygous KO cell clones, related data, and project reports.

View all
img1 img2
CRISPR-U™ Technique

CRISPR-U™ is the technique developed by Ubigene for gene editing in cell lines (based on CRISPR/Cas9). It includes a unique algorithm for designing gRNA based on cell genome characteristics, methods for exploring different gene-editing parameters for thousands of cell lines, precise detection of the editing efficiency of Cell Pool, methods for improving single-cell clone formation rates, and high-throughput identification of cellular genotypes.

icon1
icon1
Exclusive innovative technique, Gene-editing efficiency improved by 10-20 times
icon2
icon2
Fast and precise identification
Saving 4 weeks to screen positive clones
icon3
icon3
300+ Success gene-editing cell lines
6000+ Success cases

Knockout Cell Service

Cell type Various types of cells including tumor cell lines, regular cell lines, IPS/ES cell lines
Service type Single / Multiple Genes Knockout
Deliverables Cell pool / Single-cell clone
Turnaround/Price Turnaround Speedy turnaround as fast as 4 weeks!
Contact Us Contact Us

300+Successful
Gene-editing Cell Line Types

Respiratory System
+
Chinese hamster lung cells(V79)Human hypopharyngeal carcinoma cell line(FaDu)Human Bronchial Epithelial Cell Line(16HBE)Human Bronchial Epithelial Cell Line(BEAS-2B)Human Non-small Cell Lung Carcinoma Cell Line(HCC827)Human Non-small Cell Lung Carcinoma Cell Line(NCI-H1299)Human Lung Squamous Cell Carcinoma Cell Line(NCI-H226)Human lung squamous cell carcinoma cell line(SK-MES-1)Human Lung Cancer Cell Line(NCI-H520)Human Lung Cancer Cell Line(Calu-1)Human Lung Cancer Cell Line(A549)
Circulatory System
+
Mouse Myoblast Cell Line(C2C12)Human Coronary Artery Endothelial Cell line(HCAEC)Rat Cardiac Myocytes(HL-1)Rat Cardiac Myocytes(H9C2)Human Umbilical Vein Endothelial Cell Line(HUVEC)
Endocrine System
+
Human Breast Cancer Cell Line(MCF7)Mouse insulinoma β cell line(NIT-1)Human Breast Cancer Cell Line(JIMT-1)Human breast cancer cell line(T-47D)Human pancreatic cancer cell line(BxPC-3)Mouse Acinar Pancreatic Cell Line(266-6)Human Prostate Cancer Cell Line(VCaP)Human Pancreatic Carcinoma Cell Line(MIA PaCa-2)Mouse medullary breast cancer cell line(E0771)Mouse pancreatic cancer cell line(Pan02)Human Metastatic Pancreatic Adenocarcinoma Cell Line(AsPC-1)Human Breast Adenocarcinoma Cell Line(SK-BR-3)Human Pancreatic Carcinoma Cell Line(PANC-1)Rat Breast Cancer Cell Line(4T1)Human Breast Cancer Cell Line(ZR-75-1)Human Breast Cancer Cell Line(MDA-MB-231)
Brain and Nervous System
+
Human glioma cell line(U251MG)Mouse microglia cell line(BV2)Immortalize Human Microvascular Endothelial Cell Line(hCMEC/D3)Mouse Anterior Parietal Bone Cell Line(MC3T3-E1 Subclone 14)Human glioblastoma cell line(U-87 MG)Rat Glioblastoma Cell Line(C6)Mouse neuroblastoma cell line(Neuro-2a)Human Neuroblastoma Cell Line(SK-N-SH)
Blood and lymphatic System
+
Human B lymphoma cell line(Su-DHL-4)Human B Cell Lymphoma Cancer Cell Line OCI-LY3(OCI-LY3)Human B Cell Lymphoma Cancer Cell Line(U2932)Human Acute Non-B Non-T Lymphocytic Leukemia Cell Line(Reh)Human myelogenous leukemia cell line(K-562)Human T lymphocyte cell line(Jurkat, Clone E6-1)Rat Basophil Leukemia Cell Line(RBL-2H3)Human Monocytic Cell Line(THP-1)Porcine alveolar macrophage cell line(3D4/21)Mouse Macrophage Cell Line(RAW264.7)
Urinary System
+
Mouse prostate cancer cell line(RM-1)Rat adrenal pheochromocytoma cell line(PC-12)Distal nephron cell line(Distal nephron cell line(JU4s))Dog Kidney Cell Line(MDCK)Human prostate cancer cell line(22RV1)Human Embryonic Kidney Cell Line(293T)Human Embryonic Kidney Cell Line(HEK293)Human Bladder Transitional Cell Carcinoma Cell Line(T24)Human bladder carcinoma cell line(5637)Human bladder carcinoma cell line(TCCSUP)
Digestive System
+
Human colon adenocarcinoma cell line(LS174T)Porcine intestinal epithelial cell line(IPEC-J2)Human hepatoma cell line(HepaRG)Mouse Hepatocarcinoma Cell Line(Hepa 1-6)Mouse Hepatocarcinoma Cell Line(H22)Human Hepatoma Cell Line(SMMC-7721)Human renal carcinoma cell line(ACHN)African green monkey kidney cell(Vero)Human renal cell carcinoma cell line(786-0)Human Esophageal Squamous Carcinoma Cell Line(KYSE-30)Human Esophageal Squamous Carcinoma Cell Line(KYSE-150)Human gastric cancer cell line(AGS)Human Gastric Cancer Cell Line(SGC-7901)Human Gastric Cancer Cell Line(HGC-27)Human hepatobiliary cancer cell line(RBE)Human hepatocellular carcinoma cell line(HuH-7)Human Hepatoma Cell Line(Hep3B)Human liver cancer cell line(Hep G2)Human Normal Hepatocytes Cell line(L-02)Human colon carcinoma cell line(T84)Human colorectal adenocarcinoma cell line(Caco-2)Human colorectal adenocarcinoma cell line(NCI-H716)Human colon adenocarcinoma cell line(DLD-1)Murine colorectal carcinoma cell line(CT26.WT)Murine Colorectal Carcinoma Cell Line(MC38)Human caucasian colon adenocarcinoma cell line(COLO 205)Human colon carcinoma cell line(RKO)Human Colon Cancer Cell Line(HT-29)Human Colon Cancer Cell Line(SW620)Human Colon Cancer Cell Line(SW480)Human Colon Cancer Cell Line(HCT 116)
Skeleton, Articulus, Soft Tissue, Derma System
+
Mouse osteoid cell line(MLO-Y4)Ameloblastoma(hTERT-AM)Mouse squamous carcinoma cell line(SCC7)Mouse myeloma cell line(Sp2/0-Ag14)Human skin squamous carcinoma cell line(A431)Murine melanoma cell line(B16-F10)Human Melanoma Cell Line(M14)Human malignant melanoma cell line(A-375)Human fibrosarcoma cell line(HT-1080)Human bone osteosarcoma epithelial cell line(U-2 OS)Human Osteosarcoma Cell Line(MG-63)
Ocular, Otolaryngologic and Oral System
+
Human retinal pigment epithelial cell line(ARPE-19)Human choroidal melanoma cell line(OCM-1)Human oral squamous carcinoma cell line(HSC3)Human Nasopharyngeal Carcinoma Cell Line(C666-1)Human Nasopharyngeal Carcinoma Cell Line(CNE2Z)Human nasopharyngeal carcinoma cell line(NPC-43)Rat Muller Cell Line(rmc-1)
Reproductive System
+
Human ovarian cancer cell line(OVCAR-3)Human Villous Trophoblast(HTR-8/SVneo)Human Ovarian Adenocarcinoma Cell Line(CAOV3)Mouse Testicular Stromal Cell Line(TM3)Mouse Pituitary Cell Line(Lbetat2)Human Ovarian Cancer Cell Line(SK-OV-3)Chinese Hamster Ovary Cell Line(CHO-K1)Mouse Embryonic Fibroblasts(NIH/3T3)Human Cervical Carcinoma Cell Line(HeLa 229)Human Cervical Carcinoma Cell Line(HeLa)
Stem Cell
+
Stem Cell(H9)Human Embryonic Stem Cell(H1)Induced Pluripotent Stem Cell(ipsc)
Knockout Strategies
Short fragment removal
Short fragment removal
Guide RNAs target introns at both sides of exon 2 and the number of bases in exon 2 is not a multiple of 3, which can cause frame-shift mutation.
Frame-shift mutation
Frame-shift mutation
Guide RNA targets the exon, and the base number of deletion is not a multiple of 3. After knockout, frame-shift mutation would cause gene knockout.
Large fragment removal
Large fragment removal
Complete removal of the coding sequence to achieve gene knockout.
img2
View Picture
Short fragment removal
Short fragment removal
01
Guide RNAs target introns at both sides of exon 2 and the number of bases in exon 2 is not a multiple of 3, which can cause frame-shift mutation.
Frame-shift mutation
Frame-shift mutation
02
Guide RNA targets the exon, and the base number of deletion is not a multiple of 3. After knockout, frame-shift mutation would cause gene knockout.
Large fragment removal
Large fragment removal
03
Complete removal of the coding sequence to achieve gene knockout.
img2
Work Flow and Validation
Strategy Design by
Red Cotton System
RNP Complex Cell Transfection
PRC Amplification Single-cell Cloning Pool Efficiency
Validation
Sanger Sequencing
Validation
QC & Cell
Cryopreservation
Selected KO-cited papers
PPP1R12B/KCNJ12/FGA knockout Hep G2 cell line-liver tumors
IF=64.8
Nature
PPP1R12B/KCNJ12/FGA knockout Hep G2 cell line-liver tumors
IF=64.8 Nature
STING1 Knockout in HeLa cell line——prevention and treatment of viral diseases
IF=32.4
Immunity
STING1 Knockout in HeLa cell line——prevention and treatment of viral diseases
IF=32.4 Immunity
TP53 Knockout in HCT116 cell line——Apoptosis
IF=16.6
Nature Communications
TP53 Knockout in HCT116 cell line——Apoptosis
IF=16.6 Nature Communications
Abstract:
In this study, the HCT116 cell line with TP53 gene knocked out constructed by Ubigene was used. By analyzing the crystal structure of the complex of p53 and the anti-apoptotic protein BCL-2, and combining biochemical and cellular experiments, this study revealed a new mechanism of p53 interacting with BCL-2 protein and promoting apoptosis, that is, p53 forms a complex with BCL-2 by directly occupying the BH3-binding pocket of BCL-2, and antagonizes BCL-2 activity by releasing pro-apoptotic BCL-2 family proteins located in the pocket, thereby promoting apoptosis[2].These structural and functional data provide a new idea for further understanding the complex regulatory mechanism of p53-mediated mitochondrial apoptosis, and also provide an important basis for developing anticancer therapeutic strategies that target protein-protein interactions to activate apoptosis. View details>>
Mutations in p53 interacting with BCL-2 reduce apoptosis
Mutations in p53 interacting with BCL-2 reduce apoptosis
ZNF432 knockout U2OS cell line——Ovarian cancer drug resistance
IF=14.9
Nucleic Acids Research
ZNF432 knockout U2OS cell line——Ovarian cancer drug resistance
IF=14.9 Nucleic Acids Research
Abstract:
ZNF protein was confirmed as a key factor regulating the genome integrity of mammalian cells. In order to explore the possibility that ZFP can be used as an effector of DNA repair based on homologous recombination (HR), Jean Yves Masson[3] team of Laval University used the ZNF432 knockout U2OS cell line constructed by Ubigene to carry out a series of experiments, and found that ZNF432 deletion in cancer cells would accelerate DNA repair, lead to the weakening of PARPi effect, and make ovarian cancer cells develop drug resistance, confirming that ZNF432 is a new HR inhibitor, which successfully broadened the new way to study the efficacy of PARPi. View details>>
Regulation of ZNF432 expression affects drug resistance of ovarian cancer cells
Regulation of ZNF432 expression affects drug resistance of ovarian cancer cells
SNORD17 Knockout in HepG2 cell line——liver tumors
IF=12.4
Cell death & differentiation
SNORD17 Knockout in HepG2 cell line——liver tumors
IF=12.4 Cell death & differentiation
Abstract:
This study reveals the regulatory role of small nucleolar RNA SNORD17 and p53 pathway in hepatocellular carcinoma, which provides a new potential target for the treatment of hepatocellular carcinoma[5] . The researchers utilized SNORD17 knockout Hep G2 cell line (constructed by Ubigene) as the key cell model. After applied with in vitro and in vivo tests, they found out that in HCC cell lines, the knockout of SNORD17 gene can significantly inhibit cell proliferation, clone formation and G1/S phase transition. View details>>
p53 mediates SNORD17 to affect HCC cell growth
p53 mediates SNORD17 to affect HCC cell growth
Pik3r1 knockout RAW264.7 cell line - Osteoporosis
IF=11.4
Redox Biology
Pik3r1 knockout RAW264.7 cell line - Osteoporosis
IF=11.4 Redox Biology
Abstract:
This article explores a new mechanism for GSTP1 affecting the osteoclast cell-related bone homeostasis through combining with a large number of in vivo and in vitro experiments, based on the Pik3r1 knockout RAW264.7 cell model constructed by Ubigene. It was the first time to interpret that the cell fate of osteoclasts is determined by S-glutathionylation via a redox-autophagy which is mediated by GSTP1. View details>>
SiNPs induces CASA mechanism
SiNPs induces CASA mechanism

×

Subscribe Us

By subscription, you consent to allow Ubigene Biosciences to store and process the information provided above to deliver the latest news, research spotlight, and promotions. You can unsubscribe from these communications at anytime.
×

Search documentation

Literature:

Name: *

Company: *

Telephone: *

Email:

Notes: After submitting the order, we will contact you as soon as possible.

request now